InsidersTradesSigma
Total declarations
Company
▲ Purchases (10 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by Greenspan Ira Scott, Président du Conseil. Officer active across 1 companies, notably Scopus BioPharma Inc.. Aggregated, 10 filings have been recorded. Total volume traded: €34k. The latest transaction was filed on 27 August 2021 — Acquisition. Regulator: SEC (Form 4). All data is free.
Declarations10 total
€460110 shares@ €4.1851.82% mcap1.3% of flow
Common Stock, par value $0.001
SEC:0001104659-21-110764·
Ideal exit: 24 May 2022 (T+270)
€460110 shares@ €4.1851.82% mcap1.3% of flow
Common Stock, par value $0.001
SEC:0001104659-21-110764:0·
Ideal exit: 24 May 2022 (T+270)
€1,877500 shares@ €3.754910.9% of flow
Common Stock, par value $0.001
SEC:0001104659-21-109182·
Ideal exit: 20 May 2022 (T+270)
€1,877500 shares@ €3.75497.44% mcap5.4% of flow
Common Stock, par value $0.001
SEC:0001104659-21-109182:0·
Ideal exit: 20 May 2022 (T+270)
€6,9202,000 shares@ €3.459940.1% of flow
Common Stock, par value $0.001
SEC:0001104659-21-108376·
Ideal exit: 16 May 2022 (T+270)
€6,9202,000 shares@ €3.459927.41% mcap20.1% of flow
Common Stock, par value $0.001
SEC:0001104659-21-108376:0·
Ideal exit: 16 May 2022 (T+270)
€3,5271,000 shares@ €3.52720.5% of flow
Common Stock, par value $0.001
SEC:0001104659-21-107826·
Ideal exit: 14 May 2022 (T+270)
€3,5271,000 shares@ €3.52713.97% mcap10.2% of flow
Common Stock, par value $0.001
SEC:0001104659-21-107826:0·
Ideal exit: 14 May 2022 (T+270)
€4,4571,100 shares@ €4.051725.8% of flow
Common Stock, par value $0.001
SEC:0001104659-21-096344·
Ideal exit: 19 Apr 2022 (T+270)
€4,4571,100 shares@ €4.051717.65% mcap12.9% of flow
Common Stock, par value $0.001
SEC:0001104659-21-096344:0·
Ideal exit: 19 Apr 2022 (T+270)
10 of 10 declarations
About Greenspan Ira Scott
Ira Scott Greenspan is the Chairman of the Board of Scopus BioPharma Inc. He oversees the board's activities and ensures good governance of the company. His experience in the biopharmaceutical sector is valuable in guiding Scopus's strategy.
